Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma

Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma

Purpose: PARP-inhibitors have potent radiosensitizing properties in pre-clinical models. To identify the maximum tolerated dose (MTD) of the PARP-inhibitor Olaparib in combination with radiotherapy in patients with head and neck cancer, a single institutional phase-I dose escalation trial was initia...

Full description

Bibliographic Details
Main Authors: Arash Navran, Abrahim Al-Mamgani, Hester Elzinga, Rob Kessels, Conchita Vens, Margot Tesselaar, Michiel van den Brekel, Rosemarie de Haan, Baukelien van Triest, Marcel Verheij
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Clinical and Translational Radiation Oncology
Subjects:
PARP inhibitor
Olaparib
Radiosensitization
HNSCC
Radiotherapy
Feasibility
Online Access:http://www.sciencedirect.com/science/article/pii/S2405630823001234

Internet

http://www.sciencedirect.com/science/article/pii/S2405630823001234

Similar Items